

Prevalence of factor V Leid G2021 0A gene mutati

Ahmet Irdem, MD, Celal Devecioglu, MD, Sabri Batun, PhD, M

ABSTRACT



From the Department of Pediatrics (Irdem, Devecioglu, Soker, Sucakli), Faculty Hematology (Batun), Faculty of Medicine, Dicle University, Diyarbakir, *Tarkey*. Received 19th July 2004. Accepted for publication in final form 6th December 2004 Address correspondence and reprint request to: Dr. Celal Devecioglu, Associate I University, 21280, Diyarbakir, *Turkey*. Tel/Fax: +90 (412) 2488440. E-mail: mcdo 580



www.smj.org.sa Saudi Med J 20

Prevalence of FVL and PG20210A mutations ... In

Table 1	-	The prevalence of factor V Leiden mutation in various
		parts of the world.

Country	N	Prevalence n (%)					
Turkey*	151	7	(4.6)				
China ²	93	0	-				
South Cyprus4	187	25	(13.4)				
United Kingdom ⁴	237	21	(8.9)				
Senegal4	96	0	-				
Australia8	500	18	(3.6)				
Spain ⁹	150	5	(3.3)				
USA4,10	4047	150	(3.7)				
Japan ¹¹	382	0	-				
Lebanon 32	174	25	(14.4)				
Germany ³³	814	56	(7)				
Jordan ³⁴	400	49	(12.3)				
Sweden ³⁵	288	32	(11.1)				
Thailand ³⁶	500	1	(0.2)				
Kirghizystan37	153	5	(3.2)				
Greece ³⁹	160	8	(5)				
Hungary ⁴¹	407	40	(9.8)				
Argentina40	498	8	(1.6)				
*present study							

Table 2 - The prevalence of prothrombin G20210A mutation in various parts of the world.

Country	N	Prevalence		
country		n	(%)	
			(0.7)	
Turkey*	151	1	(0.7)	
North Cyprus ¹⁵	110	3	(8.1)	
Kirghizystan37	153	3	(2.1)	
Azerbaijan38	110	3	(2.7)	
Greece ³⁹	160	7	(4.4)	
Hungary41	407	11	(2.7)	
Argentina42	200	4	(2)	
Europe43	5527	111	(2)	
	*present stu	ıdy		

References

- Ozyurek HE, Gurgey A. The hereditary factors that cause Thrombosis. *Katk Pediatr* 2001; 22: 170-177. 2. Bertina RM, Koeleman BP, Koster T, Rosendaal FR, Dirven RJ, de Ronde H, et al. Mutation in blood cogulation factor V associated with resistance to activated protein C. Nature 1994; 369; 64-67. 3. Poort SR, Rosendaal FR, Reitsma PH, Bertina RM. A
- common genetic variation in the 3'-untranslated region of the prothrombin gene is associated with elevated plasma prothrombin levels and an increase in venous thrombosis. Blood 1996; 88: 3698-3703.

- 4. Rees DC, Cox Clegg JB. World distribution of faktor V
- Key DS, Cox Cregg JD. Word ustribution in factor v Leiden. *Lancet* 1995; 346: 1133-1134.
 Gurgey A, Mesci L. The prevalence of factor V Leiden (1691 G-A) mutation in Turkey. *Turk J Pediatr* 1997; 39: 313-315.
- 6. Ozbek U, Tangun Y. Frequency of factor V Leiden (Arg506Gln) in Turkey. Br J Hematol 1997; 97: 504-505.
- Herrmann FH, Koesling M, Schroder W, Altman R, Jimenez Bonilla R, Lopaciuk S, et al. Prevalence of factor Leiden mutation in various populations. Genet *Epidemiology* 1997; 14: 403-411. 8. Pecheniuk NM, March NA, Walsh NA, Dale JL. Use of
- first nucleotide change technology to determine the frequency of factor V Leiden in a population of Australian blood donors. Blood Coagulation Fibrinolysis 1997: 8: 491-495
- 9. Garcia-Gala JM, Alvarez V, Pinto CR, Soto I, Urgelles MF. Menender MJ, et al. Faktor V Leiden (R506Q) and risk of venous thromboembolism: a case-control study based or the Spanish population. *Clin Genet* 1997; 52: 206-210.
- Ridker PM, Miletich JP, Hennekens CH, Buring JE. Ethnic distribution of factor V Leiden in 4047 men and women. JAMA 1997; 277: 1305-1307.
- 11. Takamiya O. Ishada F. Takamiya O, Ishada F, Kodaira H, Kitano K. APC-resistance and Mnl genotype (Gln 506) of coagulation factor V are rare in Japanese population. Thromb Haemost 1995: 74: 996-1002
- de Maat MPM, Kluft C, Jespersen J, Gram J. World distribution of factor V Leiden mutation. *Lancet* 1996: 347:
- Fujimura H, Kambayashi J, Monden M, Kato H, Miyata T. Coagulation faktor V Leiden mutation may have a racial background. Thromb Haemost 1996; 74: 1381-1382.
- 14. Dahlback B. Resistance to activated protein C caused by factor V R506Q mutation is a common risk factor for venous thrombosis. Thromb Haemost 1997; 78: 483-488.
- Gurgey A. Hiçsönmez G, Parlak H, Balta G, Celiker A. PG20210A mutation in Turkish Patients with Thrombosis. Am J Hematology 1998: 59: 179-180
- Akar N, Misirlioglu M, Akar E, Avcu F, Yalcin A, Sozuoz A. Prothrombin gene 20210 G-A mutation in the Turkish population. Am J Hematol 1998; 58: 249.
- Dopulation. Am J Ternaud 1996, 30. 249.
 Lay MJ, Wittwer CT. Real-time fluorescence genotyping of factor V Leiden during rapid-cycle PCR. Clinical Chemistry 1997; 43: 2262-2267.
 Nauch M, Marz W, Wieland H, Evaluation of the Reche Nauch M.
- Diagnostics Light Cycler-FVL Mutation Detection Kit and the Light Cycler-Prothrombin Mutation Detection Kit. Clinical Biochemistry 2000; 33: 213-216.
- Emmerich J, Rosendaal FR, Cattaneo M, Margaglione M, De Stefano V, Cumming T, et al. Combined effect of factor V Leiden and prothrombin 20210A on the risk of venous thrombomism-pooled analysis of 8 case-control studies including 2310 cases and 3204 controls. Study Group for Pooled-Analysis in Venous Thromboembolism. Thromb Haemost 2001; 86: 809-816.
- 20. Grandone E, Margaglione M, Colaizzo D, Pavone G, Paladini D, Martinelli P, et al. Lower birth-weight in neonates of mothers carrying factor V G1691A and factor
- IIA(20210) mutations. Haematologica 2002; 87: 177-181.
 Pipe SW, Schmaier AH, Nichols WC, Ginsburg D, Bozynski ME, Castle VP. Neonatal purpura fulminans in association with factor V R506Q mutation. J Pediatr 1996. 128: 706-709.
- 22. Nowak-Gottl U, Binder M, Dubbers A, Kehrel B, Koch HG. Veltmann H. et al. Arg506 to Gln mutation in the factor V gene causes poor fibrinolytic response in children after venous occlusion. Thromb Haemost 1997; 78: 1115-1118.
- 23. Martinelli I, Landi G, Merati G, Cella R, Tosetto A, Mannucci PM. Factor V gene mutation is a risk factor for cerebral venous thrombosis. Thromb Haemost 1996; 75: 393-394
- 24. Zuber M. Toulon P. Marnet L. Mas JL. Factor V Leiden mutation in cerebral venous thrombosis. Stroke 1996; 27: 1721-1723

- 25. Hunt BJ. Activated protein C and retinal vein occlusion. Br J Ophthalmol 1996; 80: 194.
- J Opnituation 1996; 60: 1994.
 26. Larsson J, Olafsdottir E, Bauer B. Activated protein C resistance in young adults with central retinal vein occlusion. Br J Ophthalmol 1996; 80: 200-202.
- 27. Larsen TB, Norgaard-Pedersen B, Lundemose JB, Rudiger N, Gaustadnes M, Brandslund I. Sudden infant death syndrome, childhood thrombosis, and presence of genetic risk factors for thrombosis. Thromb Res 2000; 98: 233-239.
- 28. Mercuri E, Cowan F, Gupte G, Manning R, Laffan M, Rutherford M. Prothrombic disorders and abnormal neurodevelopmental outcome in infants with neonatal cerebral infarction. Pediatrics 2001; 107: 1400-1404.
- Verity DH, Vaughan RW, Madanat W, Kondeatis E, Zureikat H, Fayyad F, et al. Factor V Leiden mutation is associated with ocular involvement in Behcet disease. Am J Ophthalmol 1999; 128: 352-356.
- 30. Akar N. Akar E. Dalgin G. Sözüöz A. Ömürlü K. Cin S. Frequency of Factor V (1691 G-A) Mutation in Turkish Population. *Thromb Haemost* 1997; 78: 1527-1528.
- 31. Gul A, Ozbek U, Oztürk C, Inanç M, Koniçe M, Ozçelik T. Coagulation Factor V Gene Mutation increases the risk of venous thrombosis in Behcet's Disease. Br J Rheumatology 1996: 35: 1178-1180.
- 32. Irani-Hakime N, Tamim H, Kreidy R, Almawi YW. The prevalence of factor V R506Q mutation-Leiden among apparently healthy Lebanese. Am J Hematology 2000; 65: 45-49
- 33. Schroder W, Koesling M, Wulff K, Wehnert M, Herrmann FH. Large-scale screening for factor V Leiden mutation in north-eastern German population. Haemostasis 1996: 26: 233-236
- Awidi A, Shannak M, Bseiso A, Kailani MA, Anshasi B, Omar N, et al. High prevalence of factor V Leiden in healthy Jordanian Arabs. *Thromb Haemost* 1999; 81: 582-584
- Zoller B, Norlund L, Leksell H, Nilsson JE, von Schenck H, Rosen U, et al. High Prevalence of the FVR506Q mutation causing APC resistance in a region of southern Sweden with a high incidence of venous thrombosis. Thromb Res 1996; 83: 475-477. 36. Angchaisuksiri P, Pingsuthiwong S, Aryuchai K,
- Busabaratana M, Sura T, Atichartakarn V, et al. Prevalence of the G1691A mutation in the factor V gene (factor V Leiden) and the G20210A prothrombin gene mutation in the Thai population. Am J Hematol 2000; 65: 119-122
- 37. Gurgey A, Kudayarov DK, Tuncer M, Parlak H, Altay C. The factor V Leiden and prothrombin G20210A mutations in Kirghiz population. Thromb Haemost 2000; 84: 356.
- Kirginz population. *Intromo Haemost* 2000; 84: 556.
 Togrul J, Rustamov R, Gurgey A, Altay S, Altay C. Prevalence of the prothrombin gene G20210A mutation in Azerbaijan. *Br J Haematol* 2000; 108: 887-888.
- Antoniadi T, Hatzis T, Kroupis C, Economou-Petersen E, Petersen MB. Prevalence of factor V Leiden, prothrombin G20210A, and MTHFR C677T mutations in a Greek population of blood donors. Am J Hematol 1999; 61: 265-267.
- 40. Hepner M, Roldan A, Pieroni G, Frontroth JP, Serviddio RM, Torres AF, et al. Factor V Leiden mutation in the Argentinean population. *Thromb Haemost* 1999; 81: 989.
- 41. Balogh I, Poka R, Pfliegler G, Dekany M, Boda Z, Muszbek L. High prevalence of factor V Leiden mutation and 20210A prothrombin variant in Hungary. Thromb Haemost 1999: 81: 660-661.
- 42. Adamczuk Y, Iglesias Varela ML, Forastiero R, Martinuzzo M, Cerrato G, Pombo G, et al. Factor V Leiden and prothrombin G20210A variant are risk factors for venous thromboembolism in the Argentinean population. Thromb
- Haemost 2000; 83: 509-510.
 43. Rosendaal FR, Doggen CJ, Zivelin A, Arruda VR, Aiach M, Siscovick DS, et al. Geographic distribution of the 20210 G to A prothrombin variant. Thromb Haemost 1998; 79: 706-708.
- 44. Ayyildiz O, Kalkanli S, Batun S, Aybak M, Isikdogan A, Tiftik N et al. Prothrombin G20210A gene mutation with light cycler polymerase chain reaction in venous thrombosis and healthy population in the southeast of Turkey. *Heart Vessels* 2004 (in press).